Book your free consultation and lets create a personalized peptide protocol that helps you feel like yourself againor better than you ever have
GLP-1 users preference for smaller, more frequent eating occasions creates demand for portion-controlled, protein-forward formats
It was launched in China in December 2016
Some plans cover these medications for patients with documented obesity -related health conditions
In the SURMOUNT trials evaluating tirzepatide for chronic weight management (Zepbound), constipation occurred in 17-26% of patients depending on the dose, compared to 4% in the placebo group
The most common side effects were nausea, diarrhea, constipation, dysesthesia, and vomiting , and they were more likely at higher doses